Drug Shortages and Discontinuations

medSask is grateful for the additional financial support provided by:

pas.jpg     scfp.jpg     shrf.png     srna.png     logocpsslogotransparent-300-4x4-rgb.png

Drug shortages can occur for a variety of reasons.The factors currently affecting drug supply are shortages of raw materials, quality control issues which lead to voluntary withdrawal and longer production times for some products and competition among drug manufacturers. The problem is expected to ease somewhat with renewed production in some cases and takeover of supply by another company in others. For more details see the environmental scan on Drug Supply Disruptions posted on the CADTH website.

In the meantime, healthcare providers are responsible for ensuring patients continue to receive appropriate drug therapy. A general protocol to follow in handling drug shortages is offered below:

  1. Ensure there is a valid indication for the drug. Review the patient’s drug and medical history. For a checklist of criteria to consider, check the CPhA Drug Shortages Guide pg 4 - 6.
  2. Substitution of a different brand of the same drug (molecule):
    • Check the Saskatchewan Prescription Drug Plan (SPDP) Formulary for interchangeable brands of the same drug; then check for availability of these brands. (Call wholesalers, manufacturers)
    • If none are available, is there a non-interchangeable brand of the same drug in the same dosage form? Obtain authorization for substitution from prescriber, start at same dose or a reduced dose and titrate to desired effect (especially important if drug has a narrow therapeutic index) and monitor for beneficial and adverse effects. Follow-up with the patient in 24 – 48 hours, as indicated by kinetic and pharmacologic characteristics of the drug.
    • If no Formulary drug in the same dosage form is available, check Health Canada Drug Product Database for other brands that may be available and proceed as above.
    • If none available, is there a different dosage form of the same drug? Obtain authorization for substitution from doctor, start at appropriate dose and titrate to desired effect (especially if narrow therapeutic index) and monitor for beneficial and adverse effects. Follow-up with the patient in 24 – 48 hours as indicated by kinetic and pharmacologic characteristics of the drug.
    • If no Formulary drug is available, check Health Canada Drug Product Database for other dosage forms that may be available and proceed as above.
    • If none available, is there a different dosage form of the same drug? Obtain authorization for substitution from prescriber, start at appropriate dose and titrate to desired effect (especially if narrow therapeutic index) and monitor for beneficial and adverse effects. Follow-up with the patient in 24 – 48 hours as indicated by kinetic and pharmacologic characteristics of the drug.
    • As necessary, consult SPDP regarding coverage for substituted brand.
  3. If no other forms of the same molecule are available, substitution of another drug in the same therapeutic class can be considered. Check the references below for dose equivalence data. This information is not always available. Even when a therapeutically equivalent dose is administered, patients may react differently. Pharmacists should follow-up with the patient frequently until the patient is stabilized on the new medication.
    • Rx Files Charts - www.rxfiles.ca
    • e-therapeutics + (available at SHIRP)
    • Handbook of Clinical Drug Data , 2010, 11th edition - hardcopy text
  4. If there is not a therapeutic equivalent, check treatment guidelines and recommend a drug from another pharmacologic class. Monitor and titrate to desired effect.
  5. Compounding capsules or tablets in the desired doses when other strengths of drug are available or from bulk powders may be another option, especially in instances where there is not a readily available or acceptable substitute.

In order to provide greater information to health care practitioners and the general public, Canada’s Research Based Pharmaceutical Companies (Rx&D) and the Canadian Generic Pharmaceutical Association (CGPA) began collecting information on behalf of their individual member companies on current and impending drug shortages in the fall of 2011. Rx&D has now turned over its database architecture (i.e. the former Rx&D Drug Shortages Database) and opened its use to non-Rx&D members (i.e. all market authorization holders) who are authorized to sell medicines in Canada, and who may need to use the site to report a drug shortage.  Information is being provided on a voluntary basis.  It does not necessarily include all pharmaceutical companies in Canada, and therefore there may be gaps in the data. The new database is called  Drug Shortages Database Canada:

medSask is not responsible for the content of this database, and does not assume any liability that may arise from any use of or reliance on the information contained therein.  The information in the database has been provided by drug manufacturers, and is presented here for reference purposes only.  There is no warranty, representation or guarantee with respect to the accuracy, timeliness or completeness of this information.  medSask accepts no responsibility for any errors or omissions, and expressly disclaims any such responsibility.

medSask cannot accept phone, email, fax, or other inquiries about the content of this information.  Inquiries regarding specific drug shortages should be directed to the appropriate drug manufacturer as identified.  Questions about alternatives for shorted drugs and drug plan coverage for alternatives may be directed to the appropriate provincial drug information service.

The following tables provide suggestions for handling shortages of specific drugs. This information is intended for use by healthcare providers for general informational purposes only.  It remains the responsibility of the healthcare provider to use professional judgment in evaluating this information in light of any relevant clinical or situational data.  This information is provided without warranty of any kind and medSask and the University of Saskatchewan assume no responsibility and/or legal liability whatsoever for any errors, omissions or inaccuracies contained therein.

Specific Drug Shortages & Discontinuations

To check current availability status of Sandoz parenteral drugs go to the Sandoz website.

 
Drug Availability / Alternatives
5-AMINOSALICYLIC ACID (MESALAMINE)

400mg Asacol® has been discontinued.

Teva 400mg 5-ASA tablet (DIN 02171929) currently available. Not interchangeable with Asacol® as per the SK Formulary. 

For more information:  https://www.rxfiles.ca/RxFiles/uploads/documents/members/Cht-IBD-UC-Crohns .pdf and eCPS - Inflammatory bowel disease. Both subscription only but available through SHIRP

Acenocoumarol

Sintrom® 1mg and 4mg tablets have been discontinued.

Acenocoumarol is approximately twice as potent as warfarin.  See eCPS  (subscription). Available through SHIRP                  

Auralgan Otic Drops (antipyrine 5.4% & benzocaine 1.4%)

Estimated availability: Feb 11/22

Possible alternative: Polysporin Plus Pain Relief Ear Drops. These contain lidocaine 50 mg/mL & polymyxin B sulfate 10 000 IU/mL.

Beclomethasone dipropionate 0.025% cream

Propaderm® cream is shorted. Estimated availability: Mar 3/22.

Alternatives:  Corticosteroid creams with similar potencies can be found in the RxFiles - Topical Corticosteroid Comparison Chart. Available through SHIRP  

Beta-blocker Ophthalmic Drops

Timoptic® XE (timolol 0.5% - Elvium brand) available.

Timolol ophthalmic solution 0.5% currently available.

See DPEBB Bulletin #739: Effective July 22,2020 Health Canada has approved the import of Pharma-Stulln Timolol 0.5% ophthalmic solution. It will be temporarily listed as a full Formulary benefit and not interchangeable with other timolol ophthalmic solutions.

Betoptic® S (betaxolol) available.

Betagan® (levobunolol) and generics discontinued.

Combination products: timolol/dorzolamide, timolol/brimonidine,timolol brinzolamide, timolol latanoprost, timolol/travoprost currently available.

See eCPS (subscription) Glaucoma treatment algorithm for alternatives. eCPS is available through SHIRP.

Buprenorphine extended-release injection (Sublocade®)

Health Canada has approved importation of US-labelled product. See manufacturer's risk communication here

See Bulletin #745 (October 1, 2020) from DPEBB regarding temporary SK Formulary inclusion of Buprenorphine extended-release injection.

Drug Availability
Calcitonin, Salmon, synthetic

Calcimar® 200U/ml (2ml) INJECTION available

Calcitonin (salmon synthetic) injectable remains on the market but is indicated only for Paget’s Disease and hypercalcemia. Due to the increased cancer risk the duration of treatment should be limited to the shortest period of time possible and the minimum effective dose.

All nasal spray calcitonin products have been withdrawn and discontinued from the market due to a small increased rate of cancer (up to 2.4 %). DINs became inactive October 1st, 2013.

Carbamazepine oral suspension

Taro-carbamazepine suspension shorted - estimated availability date - Feb 6/22

Tegretol® suspension shorted - estimated availability date - Feb 21/22

Alternatives:

  • 100mg & 200mg chewable tablets
  • immediate release tablets can be dispersed in water for enteral use
Ciprofloxacin XL

Cipro XL 500mg & 1000mg are shorted - indeterminate availability

Alternative:

  • PMS - ciprofloxacin XL 500mg tablet is available
Clomiphene

Clomid® and Serophene® - discontinued

Alternatives:
Compounded by compounding pharmacy or pharmacological alternatives.

 PDF

Codeine 10mg/5ml; pseudoephedrine 30mg/5ml; triprolidine 2mg/5ml

Cotridin Syrup is shorted with indeterminate availability.

Alternatives:

  • Cotridin Expectorant Syrup also contains guaifenesin 100mg/5ml however it is currently shorted with availability date of Jan 24/22
  • Calmyin ACE Syrup has the same strength of codeine as Cotridin but also contains guaifenesin 100mg/5ml and pheniramine 7.5mg/5ml
Colestipol

Colestid® granules and tablets are shorted with indeterminate availability date. 

Alternatives:  The bile acid sequestrants cholestyramine and colesevelam are available in both powder and tablet form.  See RxFiles Lipid Lowering Therapy: Drug Comparison Chart (subscription) for dosing details.  RxFiles is available through SHIRP

Contraceptives (Oral)

For discontinued products refer to SK Formulary, for similar ingredients or RxFiles Oral Hormonal Contraception: Supplementary Tables, for similar hormonal activity.

Co-trimoxazole (sulfamethoxazole/trimethoprim) oral 

The AA brand of the DS, regular and pediatric strengths are available
Suspension - no date for availability. 
See PDF for management options 

Drug Availability
Dipyridamole/ASA

Aggrenox® has been discontinued.

Taro Dipyridamole/ASA 200mg/25mg available 

See PDF for alternatives.       

Disopyramide

Rythmodan® shorted - estimated availability: Mar 7/22

Refer to Cardiology for management.

Drug Availability
Enoxaparin

Lovenox® HP 100mg, 120mg and 150mg prefilled syringes and the 100mg/ml vial are available.

All other Lovenox® products are on allocation. For more information contact Sanofi Customer Service: 1-800-265-7927 or lavalcs@sanofi.com 

Alternatives: Most strengths can be found in the biosimilar enoxaparin products: Inclunox®, Noromby™ or Redesca® . Please note that the SK Drug Plan does not consider the biosimilar products interchangeable with Lovenox®. See DPEBB bulletin

Erythromycin Base

AA-Erythro 250mg - currently on backorder.  Estimated availability: Mar 10/22

Alternatives: Eryc® 333mg; can be compounded

Estrogens (conjugated) /bazedoxifene acetate

Duavive® - Currently on backorder. Indeterminate availability.

Indication: Treatment of vasomotor symptoms associated with menopause.

Alternatives: Estrogen + progestin

Fluphenazine decanoate injection

Oral dosage forms available.

Both brand name (Modecate®) and generic products have been discontinued.
See PDF for alternative antipsychotic depot injectables.

gramicidin 0.025 mg/mL/polymyxin B sulfate 10 000 units/mL

Optimyxin eye/ear drops shorted. Estimated availability: Apr 11/22 Alternatives: Polysporin drops are available

Drug Availability
Hydrocortisone tablets

Hydrocortisone (Cortef™) 10mg and 20mg are available.

See Pfizer's communication to pharmacies, dated 17 Dec 2020. French version is here.

5 mg tablets are accessible through the Special Access Programme.

See PDF for conservation strategies and information related to use in adrenal insufficiency. French version here

Hydrocortisone 2.5% cream

Sandoz Hydrocortisone 2.5% cream is shorted - estimated availability: Feb 19/22. No other brands are available.

Alternatives: Can be compounded

Hydrocortisone enema

Cortenema® has been discontinued.

Alternatives: Other corticosteroid enemas are available:

  • Betnesol® (betamethasone sodium phosphate) - (to be discontinued in Jun/22)
  • Entocort®  (budesonide) 
Hydromorphone Oral Suspension

Dilaudid® Oral Suspension has been discontinued.

PMS-Hydromorphone oral suspension is now available.

Alternatives:

  • An oral suspension can be compounded.
  • Switch to an alternate opioid available in an oral liquid eg morphine.  See Opioid Manager for more details. 

 

Irbesartan

As of May, 2021, several manufacturers are recalling various lots of irbesartan and irbesartan-HCTZ. See Health Canada for more information and a list of affected products. 

Recalls of further lots/manufacturers may ensue. Should irbesartan become unavailable, refer to Angiotensin II Receptor Blocker Comparison. This document is being updated to reflect the current situation.

Iron dextran injection

Dexiron has been discontinued

For alternatives see PDF

Drug Availability
Losartan

As of May, 2021, some manufacturers have recalled various lots of losartan. See Health Canada for more information and a list of affected products. 

Recalls of further lots/manufacturers may ensue. Should all brands of losartan become unavailable, see Angiotensin Receptor Antagonist (ARB) comparison chart for information about switching to a different ARB. This document is being updated to reflect the current situation.

Medroxyprogesterone
acetate injectable suspension 150 mg/mL (Depo-Provera®)

Depo-Provera® 150mg/ml is shorted - estimated availability date: Jun 1, 2023

Health Canada has approved importation of US-labelled product. Note the US-labelled product is only indicated for contraception and is available in a prefilled syringe. See Pfizer information here.

Regarding interchangeability:
If the prescription authorizes the dispensing of a particular strength and dosage of medroxyprogesterone acetate without specifying a specific brand or product name, then a pharmacist may dispense the US-labelled medroxyprogesterone acetate (Depo-Provera CI) 150mg/mL pre-filled syringes.

If the prescription directs the dispensing of Depo Provera®, a new prescription would be required in order to dispense the US-labelled medroxyprogesterone acetate (Depo-Provera CI) 150mg/mL pre-filled syringes.

See the DPEBB Bulletin for more information.

Morphine HP 50mg/ml

Sandoz Morphine HP 50mg/ml 50 ml is shorted due to a manufacturing disruption. Approximate availability date is Apr 10/2022 

At this time, the 10 ml size is still available 

Morphine  - Slow Release

Kadian® 20mg, 50mg & 100mg are available

Alternatives:

Pain management: See Opioid Manager

OAT: See the British Columbia Centre on Substance Abuse directive

Morphine suppositories

Statex suppositories have been discontinued.  Some stock may still be available.

Alternatives:

  • morphine suppositories can be compounded
  • morphine SR tablets have been used rectally - off-label
Naloxone Omega, Sandoz and Teligent brands 0.4mg/ml 10 x 1ml available

NALOXONE KIT WITH 2 VIALS - available through McKesson

Contact Poison Control for emergency information in the event naloxone is unavailable.

Naloxone Kits are available to Saskatchewan residents without a prescription. Residents may access free health region funded naloxone kits at the following locations. 

Neomycin/methylprednisolone acne lotion

Neo-Medrol® acne lotion has been discontinued

Alternatives:

Nifedipine extended-release

XR 30mg and XR 60mg Mylan brand currently available. 

Adalat® XL 30mg available.

XL 20mg indeterminate availability. 

See PDF for information regarding switching to a different calcium channel blocker.

Ofloxacin

Ocuflox® 0.3% ophthalmic drops are shorted. Estimated availability: Sep 30/22

Alternatives: See RxFiles:  Anti-Infectives for Common Infections: Conjunctivitis. Available through SHIRP

Opium and Belladonna Rectal Suppositories Discontinued by manufacturer. For information:1-800-361-3062 
                                  
Therapeutic Alternatives:
Hyoscine (Buscopan) injectable, morphine suppositories, NSAID suppositories - See PDF for more details.
Oxcarbazepine

Apo-oxcarbazepine 150, 300 & 600 mg tablets are shorted with estimated availability of Apr 10/22

Alternatives:

  • Trileptal® 300 & 600mg tablets are available
  • Trileptal® 60mg/ml susp is available

Drug Availability
Phenelzine

23 Nov 2020
US-labelled product is no longer available. See ERFA's communication.

01 Oct 2020
See Bulletin #745 from DPEBB regarding temporary SK Formulary inclusion of Phenelzine.

23 Sep 2020
Health Canada has approved importation of US-labelled product. See manufacturer's risk communication here

24 Jun 2020
As per Health Canada, “due to a global shortage of Nardil (phenelzine sulfate), a potent monoamine oxidase inhibitor (MAOI) indicated for the treatment of certain types of depressed patients, intermittent shortages of the product will be experienced in Canada. Healthcare professionals are advised to ensure no new patients are started on Nardil, consider switching patients taking Nardil to an alternative treatment and avoid abrupt discontinuation of Nardil treatment to prevent withdrawal syndrome.“

Potassium Chloride (Slow-K®)

Slow-K® (NPN 80040226) 600 mg KCl (8 mEq K+) slow release matrix tablets have been discontinued.

Alternative long acting tablets providing 8 mEq K+:

  •    Jamp K-8 (NPN 80013005) 600 mg long acting tablet;
  •    Sandoz K-8 (NPN 02247834) 600mg long acting tablet
    Note: These products contain the same strength of KCl in a similar dosage form to Slow-K® and are the closest alternatives. However, the products are not interchangeable. If patient is near the high or low ends of the potassium reference range or if patient has a history of frequent fluctuations, closer monitoring after transition is prudent.
    Note: Inventory of the above products seems to fluctuate frequently.
Alternative solid dosage forms providing 8 mEq K+:
  • Jamp Potassium Cl ER 600mg capsules (NPN 80062704)
  • Micro-K® Extencaps (NPN 02042304)

       Note: These capsules contain the same strength of KCl in a different, yet still         modified release, dosage form. If patient is near the high or low ends of the           potassium reference range or if patient has a history of frequent fluctuations,         closer monitoring after transition is prudent.

Alternative liquid providing 1.33mEq/ml KCl+:

  • Odan-Potassium Chloride (NPN 80046782 )
  • Jamp KCl liquid (NPN 80024835)
    Note: Because the absorption pattern will be quite different between Slow-K® and the liquid, closer monitoring of all patients after transition is prudent.
Alternative long acting tablets providing 20 mEq K+:
  • Sandoz K-20 (NPN 02242261)
  • Odan K-20 (NPN 80004415)
  • JAMP K-20 (NPN 80013007)
Potassium citrate tablet

Urocit®-K 5 mEq tablets are shorted. Estimated availability: Feb 2/22

Alternatives: 10mEq tablets are available.  K-citra oral solution is also available

Prednisolone Sodium Phosphate 0.5% ophthalmic solution

Minims-Prednisolone 0.5% is on backorder with no availability date

Alternatives: Several brands of the 1% prednisolone acetate ophthalmic drops are available; Pred Mild® (prednisolone acetate) 0.12% drops are available

*Note:  The acetate suspension has greater bioavailability than the sodium phosphate solution

Prochlorperazine Injectable Injectable formulation discontinued by manufacturer.
Alternate forms: 5mg and 10 mg oral tablets available
10 mg rectal suppository Available
Therapeutic alternatives: See PDF.
Progesterone - micronized

All generic brands of micronized progesterone capsules are currently shorted with availability dates ranging from Jan 21 to Feb 11/2022.

*Jan 14 - PMS brand now available*

McKesson still has Prometrium 100mg capsules in stock.

Promethazine oral Histantil 50mg tablets available.
See PDF for injectable promethazine for alternatives
Promethazine injectable Injectable formulation has been discontinued by manufacturer
Alternate forms: 50 mg oral tablets available. For information call 1-866-926-7653
Bulk chemical listed in Medisca catalogue.
Therapeutic alternatives: See PDF.
Propylthiouracil 

Discontinued distribution in Canada by Paladin.

Australian product by Phebra has been authorized by Health Canada and is available at McKesson.

See Bulletin #738 (July 15, 2020) from DPEBB regarding temporary SK Formulary inclusion of Phebra brand PTU 50 mg.

Therapeutic alternative: methimazole is the only alternative antithyroid drug in Canada.
Dose conversion imprecise. Usual maintenance doses in Graves' disease: 
Propylthiouracil: 100-150 mg PO daily in 2-3 divided doses
Methimazole: 5-15 mg PO once daily

Pyrantel pamoate suspension

Jamp Pharma Pyrantel Pamoate suspension 50mg/ml is shorted. Estimated availability: Jan 7/2023
Combantrin® suspension has been discontinued.

Alternatives:
Combantrin® 125 mg tablets available. Jamp brand 125mg tablets available.
For patients unable to take tablets, the tablet can be crushed and mixed with a soft food immediately before administering.
Vermox® (mebendazole) 100mg by prescription is available.

Albendazole is available only through Health Canada’s Special Access Program (SAP).

Drug Availability
Quinagolide

Quinagolide (Norprolac®) has been discontinued.

For alternatives see PDF

Ranitidine injectable Currently not available through McKesson. Under allocation. Contact Sandoz at 1-800-361-3062.

Change to alternative if required:
Alternative H2 antagonists:
-IV: famotidine (APX, Omega) – in short supply
-Oral: famotidine 40 mg ~ nizatidine 300 mg ~ ranitidine 150 mg BID or 300 mg HS

Alternative PPIs:
IV: Pantoprazole 
Oral: Pantoprazole 40 mg ~ Lansoprazole 30 mg ~ Omeprazole 20 mg ~ Esomeprazole 40 mg ~ Rabeprazole 20 mg
Nasogastric administration: lansoprazole, esomeprazole.
Ranitidine oral solution

Indeterminate availabilty.
If dose corresponds to tablet strength (75, 150, 300 mg), tablet can be crushed and mixed with soft food such as applesauce immediately before administering.
Extemporaneous compounding: See PDF for details.
Alternatives: See PDF for details

Ranitidine tablets

Some generics intermittently available.

Ranitidine, histamine H2-receptor antagonist (H2RA), contamination with N-nitrosodimethylamine (NDMA) has prompted a recall of both the 150mg and 300mg tablets.

Testing methodology is being developed by Health Canada with ranitidine manufacturers to determine the extent of the problem, and whether additional H2RA products may be recalled.

See PDF for alternatives.

Silodosin

Rapaflo® capsules have been discontinued.  No other brand is available.

Alternatives: Other medications in the alpha1-adrenergic receptor antagonist family are available - alfuzosin, doxazosin, tamsulosin and terazosin.  See eCPS (subscription) Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia for details. eCPS is available through SHIRP.

Sodium phosphate effervescent tablets Phosphate-Novartis - discontinued
Jamp-Sodium Phosphate 500mg - available
See PDF for alternatives.

sodium citrate/​sodium lauryl sulfoacetate/​sorbitol/​glycerin/​sorbic acid enema

Microlax enemas (12 pack) are discontinued. The manufacturer has a 4 pack available for hospital orders. There is no micro enema alternative. 

Fleet regular and Lax-a-Nema are now available. The pediatric forms of both have been discontinued.

Sulfamethoxazole/trimethoprim

See Co-trimoxazole

Sumatriptan nasal spray

Imitrex® Nasal Sprays 5mg and 20mg are shorted - Estimated availability: Feb 13/22

No other brands are available.  Other forms of sumatriptan are still available.

Tazarotene

Tazorac® 0.05% Gel has been discontinued

Alternatives:

  • Tazorac® 0.1% Gel and Tazorac® 0.05% & 0.1% creams are still available
Testosterone

Delatestryl (Testosterone Enanthate) - available

Taro Testosterone Cypionate 100mg/ml - available

Depo Testosterone 100mg/ml - indeterminate availability 

Oral and topical dosage forms currently available.

For alternatives: see PDF

Timolol ophthalmic

Timoptic® XE (timolol 0.5% - Elvium brand) available.

Timolol ophthalmic solution 0.5% 10ml currently available.

See DPEBB Bulletin #739: Effective July 22,2020 Health Canada has approved the import of Pharma-Stulln Timolol 0.5% ophthalmic solution. It will be temporarily listed as a full Formulary benefit and not interchangeable with other timolol ophthalmic solutions.

Combination products: timolol/dorzolamide, timolol/brimonidine,timolol brinzolamide, timolol latanoprost, timolol/travoprost currently available.

See eCPS (subscription) Glaucoma treatment algorithm for alternatives. RxTx is available through SHIRP.

Tirofiban 0.05mg/ml Aggrastat® - MANUFACTURER CANNOT SUPPLY FOR INFORMATION CALL 610-833-6050.
Trifluoperazine

AA-trifluoperazine 1mg & 2mg tablets have been discontinued

AA-trifluoperazine 5, 10 & 20mg tablets are available

Trifluridine Viroptic® ophthalmic solution 1% - indeterminate availability. For information call 800-361-4261. 
No other topical ophthalmic antivirals are currently available in Canada.
Viral conjunctivitis does not usually require treatment, however, cold compresses and ocular lubricants may be used.
If absolutely necessary - oral treatment can be tried.

Reference: eCPS - Red EyeeCPS is available through SHIRP.
Ulipristal 

Ulipristal 5mg(Fibristal) has been voluntarily withdrawn from the market in Canada due to risk of drug-induced liver injury.

See: https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2020/74063a-eng.php

Valsartan

As of May, 2021, some manufacturers have recalled various lots of valsartan. See Health Canada for more information and a list of affected products. 

Recalls of further lots/manufacturers may ensue. Should all brands of valsartan become unavailable, see ARB comparison chart for information about switching to a different ARB. This document is being updated to reflect the current situation.

Voriconazole

Vfend® oral suspension is shorted with estimated availability of Feb 11, 2022

Voriconazole 50 and 200mg tablets are available.

Trissel's Stability of Compounded Formulations - 6th Ed. has details on a compounded suspension for veterinary use. Trissel's is available through SHIRP.